Chargement en cours...
Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer
BACKGROUND: Immune checkpoint inhibitors (ICIs) targeting the PD‐1/PD‐L1 axis have changed the first‐line treatment of people with advanced non‐small cell lung cancer (NSCLC). Single‐agent pembrolizumab (a PD‐1 inhibitor) is currently the standard of care as monotherapy in patients with PD‐L1 expres...
Enregistré dans:
| Publié dans: | Cochrane Database Syst Rev |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley & Sons, Ltd
2020
|
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8094159/ https://ncbi.nlm.nih.gov/pubmed/33316104 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD013257.pub2 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|